Initiate a global confirmatory study
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Aug 2024
- Due
- 30 Jun 2025
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Planning initiation of global confirmatory study by mid-2025”
What we found
Evidence strength A What the grades mean
The company did not initiate the global confirmatory study by the mid-2025 deadline, with subsequent filings indicating plans to initiate dosing in mid-2026 or later.
-
A Larimar Therapeutics, Inc. 10-Q filed 2025-08-14
“Following feedback from FDA and EMA on the study protocol, global Phase 3 study sites in the U.S., European Union, U.K., Canada, and Australia were identified and are currently being qualified and initiated.” ✓ confirmed on the page
-
A Larimar Therapeutics, Inc. 10-K filed 2026-03-19
“we plan to initiate screening in this Phase 3 study in the second quarter of 2026, with dosing of the first patient expected in mid-2026.” ✓ confirmed on the page
Market reaction: the shares moved +5.1% against the S&P 500 over the three sessions around the disclosure (13 Aug 2025 to 18 Aug 2025). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +365 days
- 4 versions
-
Version 1 · original · stated 7 Aug 2024
Deadline 30 Jun 2025 (“mid-2025”)
-
Version 2 · stated 30 Oct 2024
Deadline 30 Jun 2025 (“mid-2025”) · wording expected
“Larimar is on track for a planned initiation of a global confirmatory/registration study planned mid-2025”
-
Version 3 · stated 24 Mar 2025
Deadline 30 Jun 2025 (“mid-2025”) · target 3 Phase · wording firm
“On track to initiate global Phase 3 study in mid-2025”
-
Version 4 · stated 24 Feb 2026
Deadline 30 Jun 2026 (“Q2 2026”) · wording expected
“Plan to initiate screening in global confirmatory Phase 3 study in Q2 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- global confirmatory study
- Where
- U.S., Europe, U.K., Canada, and Australia
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-LRMR-003002 · Corrections policy